XML 34 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 30, 2013
Sep. 30, 2016
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Sep. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Deferred revenue, net of current   $ 104,636   $ 85,132   $ 104,636
AstraZeneca Agreements [Member] | U.S./RoW [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expected upfront, non-contingent and time-based payments $ 374,000          
Upfront, non-contingent and time-based payments received     $ 62,000      
Development and regulatory approval milestones 550,000          
Commercial sales milestone 325,000          
Shared development costs       233,000    
Additional consideration based on net sales description           Low 20% range
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Shared development costs       $ 116,500    
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Development Milestones [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Receipt of development milestone payment         $ 15,000  
AstraZeneca Agreements [Member] | China [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Development and regulatory approval milestones 161,000          
Commercial sales milestone 167,500          
Proceeds from upfront payments 28,200          
Contingent payment $ 20,000          
Estimated joint development service period   2018        
Estimated joint development extended service period   2020        
Deferred revenue, net of current   $ 7,100       $ 7,100